Biotech entity
Every one of those 1 sits in a single category, fda-approval. Kelly Ryerson is most often covered alongside Alexandra Muñoz, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Kelly Ryerson, all published on July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. Kelly Ryerson is most often covered alongside Alexandra Muñoz, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Kelly Ryerson, all published on July 12, 2026. Each carries 8 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kelly Ryerson. Shared-story counts are live from our verified record — not editorial picks.
The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Source: abcnews.com · durangoherald.com
Kelly Ryerson is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
